Leukaemic transformation of Philadelphia chromosome-negative myeloproliferative neoplasms: are Asian patients different?

被引:1
|
作者
Cherian, R. [1 ]
Wong, G. C. [1 ]
机构
[1] Singapore Gen Hosp, Dept Hematol, Singapore 0316, Singapore
关键词
acute leukaemia; essential thrombocytosis; myeloproliferative; polycythaemia vera; myelofibrosis; VERA STUDY-GROUP; ACUTE BIPHENOTYPIC LEUKEMIA; ESSENTIAL THROMBOCYTHEMIA; POLYCYTHEMIA-VERA; MYELOID METAPLASIA; MYELODYSPLASTIC SYNDROMES; DIAGNOSTIC-CRITERIA; SURVIVAL; CLASSIFICATION; MYELOFIBROSIS;
D O I
10.1111/j.1445-5994.2011.02629.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Leukaemic transformation (LT) is rare in the natural history of Philadelphia(Ph) chromosome-negative myeloproliferative disorders (MPD), and has a dismal prognosis. Little literature is available on Asian patients. Aims: The aim of this study is to report a single institution experience of Asian patients who developed acute leukaemia after being diagnosed and treated for Ph chromosome-negative MPDs, and to compare the findings of this series with similar studies from the literature. Methods: Patients were recruited from the MPD registry of Singapore General Hospital, Department of Hematology. Clinical data including treatment modalities and duration of use in myeloproliferative phase, latency to LT, characteristics of leukaemia, chemotherapy administered and survival after LT were examined. Results: Over a 29-year period from 1980 to 2009, there were 22 Asian patients with LT of Ph chromosome-negative MPD of which four had polycythaemia vera (PV), nine had essential thrombocythaemia (ET), seven had myelofibrosis (MF) and two had unspecified MPD at diagnosis. Primary treatment modality was Hydroxyurea (HU) during MPD phase. Median latency to LT was 14 years for PV, 10 years for ET and 1 year for MF. Median age at LT diagnosis was 67.5 years. Nine patients had complex cytogenetics, with abnormalities of chromosomes 5 and 7 being common. Overall, median survival was 2 months after LT. Eight patients who received induction chemotherapy had a median survival of 2.5 months. Survival was independent of MPD type and treatment administered. None received stem cell transplantation. Conclusions: LT of Ph chromosome-negative MPD is rare and uniformly fatal. Despite chemotherapy, survival was poor, and patients succumbed to refractory disease and infections. Asian patients did not have a more favourable outcome. It remains to be investigated whether upfront stem cell transplant may be a treatment option.
引用
收藏
页码:513 / 517
页数:5
相关论文
共 50 条
  • [1] LEUKEMIC TRANSFORMATION OF PHILADELPHIA CHROMOSOME-NEGATIVE MYELOPROLIFERATIVE DISORDERS: ARE ASIAN PATIENTS DIFFERENT?
    Wong, G. C.
    [J]. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 604 - 604
  • [2] Impact of Comorbidities in Philadelphia Chromosome-Negative Myeloproliferative Neoplasms
    Ahmed, Shima A.
    Aly, Mai M.
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 : S336 - S336
  • [3] Concurrent lymphoid and Philadelphia chromosome-negative myeloproliferative neoplasms
    Miguel Torregrosa, Jose
    Soler, Gloria
    Cancio, Shirley
    Ferrer-Marin, Francisca
    [J]. MEDICINA CLINICA, 2015, 145 (07): : 318 - 319
  • [4] Increased Risk of Lymphoid Neoplasms in Patients with Philadelphia Chromosome-Negative Myeloproliferative Neoplasms
    Vannucchi, Alessandro M.
    Masala, Giovanna
    Antonioli, Elisabetta
    Susini, Maria Chiara
    Guglielmelli, Paola
    Pieri, Lisa
    Maggi, Laura
    Caini, Saverio
    Palli, Domenico
    Bogani, Costanza
    Ponziani, Vanessa
    Pancrazzi, Alessandro
    Annunziato, Francesco
    Bosi, Alberto
    [J]. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2009, 18 (07) : 2068 - 2073
  • [5] Somatic Mutations in Philadelphia Chromosome-Negative Myeloproliferative Neoplasms
    Cristina, Sergio Ferreira
    Polo, Blanca
    Lacerda, Joao F.
    [J]. SEMINARS IN HEMATOLOGY, 2018, 55 (04) : 215 - 222
  • [6] Epidemiology of the Philadelphia Chromosome-Negative Classical Myeloproliferative Neoplasms
    Shallis, Rory M.
    Zeidan, Amer M.
    Wang, Rong
    Podoltsev, Nikolai A.
    [J]. HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2021, 35 (02) : 177 - 189
  • [7] INCREASED RISK OF LYMPHOID MALIGNANCIES IN PATIENTS WITH PHILADELPHIA CHROMOSOME-NEGATIVE MYELOPROLIFERATIVE NEOPLASMS
    Antonioli, E.
    Susini, M. C.
    Masala, G.
    Guglielmelli, P.
    Pieri, L.
    Caini, S.
    Palli, D.
    Bogani, C.
    Pancrazzi, A.
    Longo, G.
    Bosi, A.
    Vannucchi, A. M.
    [J]. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 263 - 263
  • [8] Philadelphia chromosome-negative myeloproliferative neoplasms: clinical aspects and treatment options
    Gotoh, Akihiko
    [J]. INTERNATIONAL JOURNAL OF HEMATOLOGY, 2022, 115 (05) : 616 - 618
  • [9] Current Concepts of Pathogenesis and Treatment of Philadelphia Chromosome-Negative Myeloproliferative Neoplasms
    Zeeh, Franziska C.
    Meyer, Sara C.
    [J]. HAMOSTASEOLOGIE, 2021, 41 (03): : 197 - 205
  • [10] Cancer Immune Therapy for Philadelphia Chromosome-Negative Chronic Myeloproliferative Neoplasms
    Holmstrom, Morten Orebo
    Hasselbalch, Hans Carl
    Andersen, Mads Hald
    [J]. CANCERS, 2020, 12 (07) : 1 - 21